‹ ›
MYP_125113
← PREVIOUS NEXT → BACK
Basic Information
Filgrastim
Anticancer
Immunology ▸ Immune modulation ▸ Immunomodulatory activity
Therapeutic / Biomedical activity ▸ Enzyme replacement therapy
Standard
175 amino acids
C845H1343N223O243S9
Standard
Sequence
MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
Physicochemical Analysis
18802.64 Da
5.65
-4.09
-4.66
-0.0234
0.21
0.71
0.19
60.50
104.91
0.0629
15470.00
15720.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
7303.96
-74.69
248.0
253.0
609.0
1320.0
31.0
191.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0013844 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; Escherichia coli [Bacterium]
G-CSF
9606;562
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Hematopoietic G-CSF Neutrophil recovery
Elimination half-life, healthy subjects and cancer patients, Neopogen = 3.5 h; Elimination half-life, cancer patients, tbo-filgrastim = 3.2-3.8 h
PaperPubMed-linked source references: PMID:21456630; PMID:25637379; PMID:25631830; PMID:25594147; PMID:25581410; PMID:25524005; PMID:11677930 PMID21456630;25637379;25631830;25594147;25581410;25524005;11677930 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21456630/ PatentCA1341537
RECORD: Rec_0019570 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Growth factor
9606
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
PEGylation
Bio-Activity Profile
Anticancer Immunomodulatory Enzyme replacement
The average terminal half-life ranged from approximately 32 to 62 hours after a single subcutaneous injection of 6 mg lipegfilgrastim in healthy individuals [L2441].
Evidence URLhttps://webs.iiitd.edu.in/raghava/thpdb2/display_thppid.php?details=Th1571
RECORD: Rec_0050047 VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Enzyme
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Approximately 3.5 hours
Evidence URLhttps://webs.iiitd.edu.in/raghava/thpdb2/display_thppid.php?details=Th1181
RECORD: Rec_0091827 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Escherichia coli [Bacterium]
Growth factor
9606; 562
Structure & Mods
single-chain therapeutic peptide/protein [Linear]
canonical L-amino-acid peptide [L]
PEGylation
Bio-Activity Profile
Anticancer Immunomodulatory
15-80 hours
Evidence URLhttps://patents.google.com/patent/CA1341537/en PatentCA1341537
RECORD: Rec_0155909 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Growth factor
9606
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
PEGylation
Bio-Activity Profile
Anticancer Enzyme replacement
The average terminal half-life ranged from approximately 32 to 62 hours after a single subcutaneous injection of 6 mg lipegfilgrastim in healthy individuals [L2441].
Evidence URLhttps://webs.iiitd.edu.in/raghava/thpdb2/display_thppid.php?details=Th1571
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2